SI3506904T1 - Zdravljenje demence - Google Patents
Zdravljenje demenceInfo
- Publication number
- SI3506904T1 SI3506904T1 SI201730630T SI201730630T SI3506904T1 SI 3506904 T1 SI3506904 T1 SI 3506904T1 SI 201730630 T SI201730630 T SI 201730630T SI 201730630 T SI201730630 T SI 201730630T SI 3506904 T1 SI3506904 T1 SI 3506904T1
- Authority
- SI
- Slovenia
- Prior art keywords
- dementia
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Valve Device For Special Equipments (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1614834.8A GB201614834D0 (en) | 2016-09-01 | 2016-09-01 | Treatment of dementia |
| PCT/EP2017/071437 WO2018041739A1 (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
| EP17761842.8A EP3506904B1 (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3506904T1 true SI3506904T1 (sl) | 2021-03-31 |
Family
ID=57139937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201730630T SI3506904T1 (sl) | 2016-09-01 | 2017-08-25 | Zdravljenje demence |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10842796B2 (sl) |
| EP (1) | EP3506904B1 (sl) |
| JP (1) | JP7066679B2 (sl) |
| KR (1) | KR102559354B1 (sl) |
| CN (1) | CN109890391B (sl) |
| AU (1) | AU2017318333B2 (sl) |
| CA (1) | CA3034625A1 (sl) |
| DK (1) | DK3506904T3 (sl) |
| ES (1) | ES2847929T3 (sl) |
| GB (1) | GB201614834D0 (sl) |
| HR (1) | HRP20210162T1 (sl) |
| MX (1) | MX2019002429A (sl) |
| MY (1) | MY187564A (sl) |
| PL (1) | PL3506904T3 (sl) |
| PT (1) | PT3506904T (sl) |
| SG (1) | SG11201901125TA (sl) |
| SI (1) | SI3506904T1 (sl) |
| WO (1) | WO2018041739A1 (sl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2057136T3 (pl) | 2006-07-11 | 2013-10-31 | Wista Lab Ltd | Sposoby syntezy i/lub oczyszczania związków diaminofenotiazynowych |
| KR20210038586A (ko) | 2018-07-26 | 2021-04-07 | 위스타 레보레이토리스 리미티드 | 집단에서 디아미노페노티아진(diaminophenothiazines)의 최적 투여량 |
| KR102700017B1 (ko) | 2018-09-05 | 2024-08-29 | 젠팅 타우알엑스 다이어그노스틱 센터 에스디엔 비에이치디 | 신경퇴행성 질환에 대한 네트워크 방법 |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| WO2023232764A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| EP4342451A1 (en) * | 2022-09-22 | 2024-03-27 | Galenicum Health SLU | Pharmaceutical compositions and manufacturing methods thereof |
| US20240115579A1 (en) * | 2022-09-22 | 2024-04-11 | Galenicum Health S.L.U. | Pharmaceutical compositions and manufacturing methods thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| SI1509232T1 (sl) | 2002-05-31 | 2009-04-30 | Lundbeck & Co As H | Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni |
| ES2736160T3 (es) | 2004-09-23 | 2019-12-26 | Wista Lab Ltd | Procedimientos de síntesis química y purificación de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (CMT) |
| ES2349322T7 (es) | 2006-03-29 | 2019-10-17 | Wista Lab Ltd | Sales de 3,7-diamino-10H-fenotiazina y su utilización |
| WO2007110630A1 (en) * | 2006-03-29 | 2007-10-04 | Wista Laboratories Ltd. | Thioninium compounds and their use |
| FR2899107B1 (fr) * | 2006-03-30 | 2008-06-13 | Neurokin Entpr Unipersonnelle | Utilisation de la (s)-roscovitine pour la fabrication d'un medicament |
| PL2057136T3 (pl) | 2006-07-11 | 2013-10-31 | Wista Lab Ltd | Sposoby syntezy i/lub oczyszczania związków diaminofenotiazynowych |
| FR2903696B1 (fr) | 2006-07-12 | 2011-02-11 | Provence Technologies | Procede de purification de composes diaminophenothiazium |
| US9034890B2 (en) * | 2006-11-15 | 2015-05-19 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
| PT2167095T (pt) | 2007-06-19 | 2019-08-06 | Wista Lab Ltd | Compostos de fenotiazina para o tratamento de comprometimento cognitivo leve |
| HUE025199T2 (en) | 2007-10-03 | 2016-01-28 | Wista Lab Ltd | Therapeutic use of diaminophenothiazines |
| PL3378856T3 (pl) | 2009-09-24 | 2021-05-31 | Wista Laboratories Ltd. | Krystaliczne hydraty chlorku metylotioniny |
| JP5918136B2 (ja) | 2009-09-24 | 2016-05-18 | ウィスタ ラボラトリーズ リミテッド | プロセス |
| KR101888713B1 (ko) | 2011-02-11 | 2018-08-14 | 위스타 레보레이토리스 리미티드 | 페노티아진 디아미늄 염 및 이의 용도 |
| CN102936244B (zh) * | 2012-12-04 | 2015-02-04 | 合肥工业大学 | 一种他克林-吩噻嗪异二联体类化合物及其制备方法 |
-
2016
- 2016-09-01 GB GBGB1614834.8A patent/GB201614834D0/en not_active Ceased
-
2017
- 2017-08-25 PL PL17761842T patent/PL3506904T3/pl unknown
- 2017-08-25 CN CN201780067154.4A patent/CN109890391B/zh active Active
- 2017-08-25 PT PT177618428T patent/PT3506904T/pt unknown
- 2017-08-25 MY MYPI2019001119A patent/MY187564A/en unknown
- 2017-08-25 DK DK17761842.8T patent/DK3506904T3/da active
- 2017-08-25 CA CA3034625A patent/CA3034625A1/en active Pending
- 2017-08-25 MX MX2019002429A patent/MX2019002429A/es unknown
- 2017-08-25 ES ES17761842T patent/ES2847929T3/es active Active
- 2017-08-25 AU AU2017318333A patent/AU2017318333B2/en active Active
- 2017-08-25 SI SI201730630T patent/SI3506904T1/sl unknown
- 2017-08-25 JP JP2019511720A patent/JP7066679B2/ja active Active
- 2017-08-25 KR KR1020197009175A patent/KR102559354B1/ko active IP Right Grant
- 2017-08-25 EP EP17761842.8A patent/EP3506904B1/en active Active
- 2017-08-25 US US16/329,611 patent/US10842796B2/en active Active
- 2017-08-25 WO PCT/EP2017/071437 patent/WO2018041739A1/en active Application Filing
- 2017-08-25 SG SG11201901125TA patent/SG11201901125TA/en unknown
-
2021
- 2021-02-01 HR HRP20210162TT patent/HRP20210162T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3034625A1 (en) | 2018-03-08 |
| EP3506904A1 (en) | 2019-07-10 |
| PT3506904T (pt) | 2021-02-02 |
| PL3506904T3 (pl) | 2021-07-26 |
| AU2017318333B2 (en) | 2023-05-11 |
| KR20190045273A (ko) | 2019-05-02 |
| GB201614834D0 (en) | 2016-10-19 |
| JP2019526571A (ja) | 2019-09-19 |
| US10842796B2 (en) | 2020-11-24 |
| ES2847929T3 (es) | 2021-08-04 |
| KR102559354B1 (ko) | 2023-07-26 |
| EP3506904B1 (en) | 2020-12-09 |
| WO2018041739A1 (en) | 2018-03-08 |
| DK3506904T3 (da) | 2021-01-04 |
| CN109890391B (zh) | 2023-01-31 |
| MX2019002429A (es) | 2019-07-08 |
| US20190192530A1 (en) | 2019-06-27 |
| CN109890391A (zh) | 2019-06-14 |
| AU2017318333A1 (en) | 2019-04-18 |
| MY187564A (en) | 2021-09-30 |
| HRP20210162T1 (hr) | 2021-03-19 |
| JP7066679B2 (ja) | 2022-05-13 |
| SG11201901125TA (en) | 2019-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006746B (en) | Methods of treatment | |
| EP3483284C0 (en) | NANOVESICLES DERIVED FROM BACTERIA OF THE GENREPROPIONIBACTERIUM | |
| GB201701673D0 (en) | Methods of well treatment | |
| IL250490A0 (en) | A method for treating depression | |
| PT3506904T (pt) | Tratamento de demência | |
| GB201608885D0 (en) | Treatment | |
| GB201410116D0 (en) | Method of treatment | |
| IL290855A (en) | Treatment methods using vitamin d | |
| IL253028A0 (en) | treatment method | |
| LT3377064T (lt) | Orvepitantas, skirtas lėtinio kosulio gydymui | |
| GB201416832D0 (en) | Methods of treatment | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| PL3504163T3 (pl) | Oczyszczanie ścieków | |
| GB201602802D0 (en) | Method of treatment | |
| SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
| IL260094A (en) | Treatment of hand eczema | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| GB201512139D0 (en) | Methods of treatment | |
| GB201510870D0 (en) | Treatment of infarction | |
| GB201608599D0 (en) | Treatment of opioid tollerence | |
| GB201617107D0 (en) | Treatment | |
| GB201613350D0 (en) | Treatment of hyperpigmentation | |
| GB201612260D0 (en) | Treatment | |
| GB201612193D0 (en) | Treatment | |
| GB201609683D0 (en) | Treatment |